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Background: The effect of beta-blockers on infarct size
when used in conjunction with primary PCI is unknown. We
hypothesize that metoprolol reduces infarct size when
administered early (intravenously before reperfusion).
Methods and results: Patients with Killip class II or less
anterior STEMI undergoing PCI within 6 h of symptoms onset
were randomized to receive intravenous metoprolol (n ¼ 131)
or not (control, n ¼ 139) before reperfusion. All patients
without contraindications received oral metoprolol within
24 h. The predefined primary end pointwas infarct size onMRI
performed 5e7 days after STEMI. MRI was performed in 220
patients (81%).Mean SD infarct size byMRIwas smaller after
intravenous metoprolol compared with control (25.6  15.3 vs
32.0  22.2 g; adjusted difference, 6.52; 95% confidence
interval, 11.39 to 1.78; p ¼ 0.012). In patients with pre-PCI
TIMI grade 0 to 1 flow, the adjusted treatment difference in
infarct size was 8.13 (95% confidence interval, 13.10 to
3.16; p ¼ 0.0024). Infarct size estimated by peak and area
under the curve CK release was measured in all study pop-
ulations and was significantly reduced by intravenous meto-
prolol. LVEF was higher in the intravenous metoprolol group
(adjusted difference, 2.67%; 95% confidence interval,
0.09e5.21; p ¼ 0.045). The composite of death, malignant
ventricular arrhythmia, cardiogenic shock, AV block and re-
infarction at 24 h in the intravenous metoprolol and control
groups was 7.1% and 12.3%, respectively (p ¼ 0.21).
Conclusions: In patients with anterior Killip class II or less
STEMI undergoing primary PCI, early intravenous metoprolol
before reperfusion reduced infarct size and LVEF with no
excess of adverse events during the first 24 h after STEMI.1. Perspective
1.1. Early intravenous metoprolol in acute STEMI before
timely primary PCIeA stitch in time saves nine?
The benefit of oral beta-blockers in STEMI patient is well
known and is recommended in all STEMI patients within 24 h
unless contraindicated. Beta-blockers have pleiotropic effectson ischemic myocardium and its cardioprotective effect pri-
marily stems from reduction of ischemia reperfusion injury.
The literature on acute IV beta-blocker (BB) therapy in STEMI
patients before mechanical reperfusion is limited and reveals
conflicting results. Hence there is no clear-cut guideline
advocating routine use of early intravenous BB (EIVBB) ther-
apy in all STEMI patients.
METOCARD-CNIC is the largest prospective randomized
study in the era of mechanical reperfusion clearly showing
infarct limiting potential of EIVBB in STE AWMI patients
resulting in improved LVEF as compared to control arm. This
study forms a landmark because it attempts in a better way in
demystifying the fact that EIVBB in STEMI patients is harmful
and takes an extra step in proving significant 20% reduction in
infarct size above that achieved with mechanical reperfusion
with a trend towards reduction in adverse clinical events.
In the era when fibrinolytic therapy was not widely used,
trials on IV beta-blockers had shown mixed results. Goteborg
metoprolol trial revealed a 17% reduction in infarct size and
36% reduction in mortality with IV metoprolol when it was
administered within 7 h of symptom onset.1 MIAMI trial did
show a statistically insignificant 13% reduction in mortality
with IV metoprolol in acute MI patients administered within
12 h of symptom onset. ISIS-1 trial on 16,027 patients of sus-
pectedmyocardial infarction had shown a 15% reduction with
IV atenolol therapy. But a meta-regression analysis in the pre-
reperfusion era had demonstrated no extra mortality benefit
with IV beta-blockers.2
In the fibrinolytic reperfusion era, twomajor trials failed to
show any difference in mortality, LVEF or infarct size with
EIVBB therapy in STEMI patients reperfused with alteplase.
Both GUSTO and COMMIT trials had shown increased rates of
CHF and cardiogenic shock with EIVBB in STEMI patients.3,4
The COMMIT trial also had shown that EIVBB therapy in
STEMI patients in Killip class III increased mortality hence
nullifying the benefits like reduced reinfarction rates and
ventricular fibrillation.4 Learning lessons from COMMIT trial,
the use of EIVBB was restricted to class I and II patients in the
present study.
In the mechanical reperfusion era, again results were
mixed on EIVBB. Conflicting reports exist on cardioprotective
effect of beta-blocker therapy and post PCI procedural enzyme
release. CADILLAC investigators had shown that EIVBB
improved 30-day mortality (1.5% vs 2.8%) and LVEF only in
those patients who had not received prior beta blocker ther-
apy (3.8% vs 1.3%).5 Valle et al showed that pre-primary PCI
beta blocker use was associated with reduced arrhythmia and
mortality without increased rates of cardiogenic shock and
congestive cardiac failure.6
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dioprotection like thrombectomy devices, distal embolization
devices, glucose insulin potassium infusion, adenosine, endo-
vascular cooling etc., have yielded equivocal results because of
delayed time to reperfusion. In the present study mechanical
reperfusion was established within 6 h of symptom onset,
hence ensuring reasonable reperfusion window period.
In our opinion this is an important landmark study
showing potential cardioprotective benefit of EIVBB in STEMI
patients undergoing primary PCI within 6 h and having no
contraindications for BB and it may play a vital role in the
future in shifting the guideline for IV beta-blocker from class
IIa to class I, especially in acute anterior wall MI with sym-
pathetic stimulation and Killip class  II. The 20% greater
reduction in infarct size above that was achieved by
mechanical reperfusion offers great hope. Hence EIVBB can
be regarded as an asset with certainty for cardioprotection.
Well-designed RCTs aiming to achieve improvement in hard
clinical outcomes with EIVBB in STEMI patients is the need of
the hour.r e f e r e n c e s
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Objectives: The aim of this observational, multicenter
study was to describe the outcome of very elderly patients
undergoing percutaneous coronary intervention (PCI).
Background: There is a paucity of data among non-
agenarians undergoing PCI.
Methods: All consecutive patients 90 years of age or older
undergoing PCI with stent implantation between April 2002
and June 2009 were included in the study. The primary end-
point was the long term rate of net adverse cardiac events
(NACE), that is, death, myocardial infarction (MI), target lesion
revascularization, and life threatening or major bleedings.
Results: One hundred forty-six nonagenarians were divi-
ded in three groups according to clinical setting: 27 (group A)
stable angina or silent ischemia, 85 (group B) unstable angina
or non-ST elevation MI, and 34 (group C) with ST elevation MI
(STEMI). At 30 days, the incidence of NACE was significantly
lower in patients in Group A vs. B or C (0% vs. 17.3% vs. 31.2%,
p ¼ 0.006), and the frequency of definite stent thrombosis was
higher in Group C vs. A or B (9.4% vs. 0% vs. 0%, p ¼ 0.007),
respectively. Up to a median follow up of 24 months, NACE
rate was 33.3% in group A, 49.3% in group B, and 50% in group
C (p ¼ 0.32). There were no significant differences between
groups in the individual components of the primary endpoint.
Conclusions: PCI in nonagenarians is safe and feasiblewith
acceptable major bleeding rates. However, long term results
show high mortality rates particularly in the STEMI group.1. Perspective
1.1. NINETY e age not a PENALTY
With an increase in life expectancy, there is a significant
increase in the elderly and very elderly population. This trend
is expected to increase further in the coming years. CAD is an
important cause of mortality in the very elderly age group.
Elderly age is an independent risk factor for short term mor-
tality in CAD, especially STEMI patients. Atypical symptoms,
late presentation, lack of timely medical advice and trans-
portation to hospitals with critical care units put this pop-
ulation at high risk with increased complications and adverse
effects. Elderly and very elderly patients are usually excluded
from the major trials of revascularization and optimal treat-
ment strategies and outcomes in this subgroup are less clear.
Thrombolytic therapy was thought to be associated with
increased bleeding risks in elderly, especially intracranial
bleeding, as compared to primary PCI, but major trials testing
this hypothesis had failed to prove it.1,2 In fact, registry data
show that less than 50% of the elderly patients receive any
form of revascularization therapy despite suggested mortality
benefit. About 20e30% of these patients undergoing PCI
